RNS Number : 6156U
Blackfinch Spring VCT PLC
29 March 2023
 

 

Blackfinch Spring VCT plc (the "Company")

 

Issue of Ordinary Shares of £0.01 each ("Ordinary Shares") pursuant to an Offer for Subscription dated 2 September 2022 of up to £20 million of Ordinary Shares with an over-allotment facility for up to a further £10 million of Ordinary Shares (the "Offer")

 

 

The Company announces an allotment on 28 March 2023 in respect of 684,363 Ordinary Shares pursuant to the Offer.  In accordance with the Offer Price set out in the prospectus containing details of the Offer, the subscription prices at which Ordinary Shares were allotted ranged from 90.85p to 92.25p per Ordinary Share.

 

Following this allotment, the number of Ordinary Shares in issue is 25,250,283 (including 2 Ordinary Shares issued as subscriber shares).

 

Therefore, the total number of voting rights in the Company is 25,250,283.  This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Application for these Ordinary Shares to be admitted to the Official List of the Financial Conduct Authority and to trading on the premium segment of the London Stock Exchange's main market for listed securities will be made shortly and dealings are expected to commence on or around 14 April 2023.  CREST accounts are expected to be credited as soon as practicable following the allotment and definitive documents of title are expected to be dispatched within ten business days of allotment.

 

 

 

For further information, please contact:

 

Blackfinch Investments Limited (Investment Manager)

01452 717070

 

The City Partnership (UK) Limited (Company Secretary)

enquiries@city.uk.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEVKLBLXXLLBBD